Section two
- More than one-quarter of QT interval prolongation inducing drugs were
prescribed for patients with end stage renal disease based on
inappropriate decisions.
- Around two-thirds of dispensed QT interval prolongation inducing drugs
had pharmacokinetic and pharmacodynamics interactions with other
drugs, more than one-third of these interactions were major and
moderate
- Absence of major polypharmacy and co-morbidity decreased the odds of
major drug-drug interactions by 61% and 72%, respectively.